SCHEMBL4037511

SCHEMBL4037511

O=C(O)Cn1c2c(c3ccccc31)CCCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 1.00
GLA P06280 2/20 1.00
MEN1 O00255 1/20 1.00
CASP1 P29466 1/20 1.00
CASP7 P55210 1/20 1.00
KMT2A Q03164 1/20 1.00
HSD17B10 Q99714 1/20 1.00
ALDH1A1 P00352 1/20 0.74
CA1 P00915 3/20 0.63
CA2 P00918 3/20 0.63
PTGDR2 Q9Y5Y4 7/20 0.62
CYP2C9 P11712 2/20 0.61
HDAC1 Q13547 2/20 0.57
HDAC6 Q9UBN7 2/20 0.57
HDAC10 Q969S8 1/20 0.57
HTR6 P50406 1/20 0.56
PTGER2 P43116 1/20 0.55
PTGDR Q13258 1/20 0.55
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8773238 0.85 KDM4E (1.00) KDM4EGLAMEN1CASP1CASP7
SCHEMBL14197444 0.84 KDM4E (0.72) KDM4EGLAMEN1CASP1CASP7
SCHEMBL10152135 0.83 HSD17B10 (0.71) KDM4EGLAMEN1CASP1CASP7
Hydrochloric Acid SCHEMBL6484333 0.83 KDM4E (0.71) KDM4EGLAMEN1CASP1CASP7
SCHEMBL14487450 0.81 KDM4E (0.68) KDM4EGLAMEN1CASP1CASP7
SCHEMBL15281763 0.81 KDM4E (0.68) KDM4EGLAMEN1CASP1CASP7
SCHEMBL4090444 0.81 KDM4E (0.67) KDM4EGLAMEN1CASP1CASP7
SCHEMBL5627158 0.80 KDM4E (0.67) KDM4EGLAMEN1CASP1CASP7
SCHEMBL28566130 0.80 KDM4E (0.67) KDM4EGLAMEN1CASP1CASP7
Acetic Acid SCHEMBL9518648 0.80 CA1 (0.78) KDM4EGLAMEN1CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2051962-A1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-04-29 EP claimed
WO-2008017989-A1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-02-14 WO claimed
EP-1833791-A2 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2007-09-19 EP claimed
WO-2006070325-A2 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2006-07-06 WO claimed
US-12091708-B2 Compositions and methods targeting the Th2 pathway for the treatment of asthma THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2024-09-17 US disclosed
EP-3565635-B1 METHODS FOR DIAGNOSING ASTHMA AND COMPOSITIONS FOR USE IN TARGETING THE TH2 PATHWAY IN THE TREATMENT OF ASTHMA CHILDRENS HOSPITAL PHILADELPHIA (US) 2023-09-27 EP disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 US disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 US disclosed
EP-3565635-A1 COMPOSITIONS AND METHODS TARGETING THE TH2 PATHWAY FOR THE TREATMENT OF ASTHMA The Children's Hospital of Philadelphia (US) 2019-11-13 EP disclosed
US-10370358-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2019-08-06 US disclosed
WO-2018129529-A1 COMPOSITIONS AND METHODS TARGETING THE TH2 PATHWAY FOR THE TREATMENT OF ASTHMA THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2018-07-12 WO disclosed
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 US disclosed
EP-2729448-A1 COMPOUNDS FOR THE TREATMENT OF HIV Gilead Sciences, Inc. (US) 2014-05-14 EP disclosed
WO-2013006738-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2013-01-10 WO disclosed
EP-2423190-A1 Compounds Exhibiting PGD 2 Receptor Antagonism Shionogi&Co., Ltd. (JP) 2012-02-29 EP disclosed
EP-2051962-A1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-04-29 EP disclosed
WO-2008017989-A1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-02-14 WO disclosed
EP-1833791-A2 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2007-09-19 EP disclosed
WO-2006070325-A2 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2006-07-06 WO disclosed
WO-2004063156-A1 NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS BIOVITRUM AB (SE) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370358-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN KDM4E 1590/4885GLA 1751/4885MEN1 2645/4885
US-20180194746-A1 Compounds For the Treatment of HIV CCR5, NPC1, FURIN KDM4E 1590/4885GLA 1751/4885MEN1 2645/4885
US-11034668-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN KDM4E 1590/4885GLA 1751/4885MEN1 2645/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN KDM4E 1590/4885GLA 1751/4885MEN1 2645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.